Every Form 4 that IGC Pharma, Inc. (IGC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow IGC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IGC filings page.
IGC Pharma, Inc. CEO and director Ram Mukunda reported two gifts of 100,000 common shares each on September 25, 2026, totaling 200,000 shares. A footnote identifies the recipients as his two children, who do not share his household. Both transactions are reported as direct gifts.
IGC Pharma, Inc. director and PFO Claudia Grimaldi reported a bona fide gift of 150,000 common shares on September 25, 2026. The recipient was her child, who does not share her household. After the transaction, Grimaldi directly held 3,271,092 shares.
IGC Pharma CEO Mukunda Ram acquired 2,226,475 shares of common stock in a private placement by cancelling $601,148 of debt the company owed him. The shares were issued at $0.27 each as restricted securities under Rule 144, in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933. The deal was approved in advance by disinterested directors and the Audit Committee for Rule 16b-3 purposes, and Ram now directly holds 6,875,563 shares of IGC Pharma common stock.
IGC Pharma director and principal financial officer Claudia Grimaldi acquired 2,048,378 shares of common stock in a debt-for-equity swap. The shares were obtained at $0.27 per share in a private placement in exchange for cancellation of $553,062 of indebtedness owed to her by the company.
Following this transaction, she directly holds 3,421,092 common shares. The new shares are restricted securities under Rule 144 and were issued under a Section 4(a)(2) private placement exemption, with approval by disinterested directors and the Audit Committee for Rule 16b-3 purposes.
IGC Pharma director Richard K. Prins exercised restricted stock units into common shares of the company. On April 1, 2026, he converted 170,000 restricted stock units into 170,000 shares of common stock at an exercise price of $0.00 per share. Following these transactions, he directly holds 1,541,251 shares of IGC Pharma common stock. The units were granted in June 2023 and March 2024 and vest in equal installments over three years, with each unit representing one share of common stock.
IGC Pharma, Inc. CEO Mukunda Ram reported multiple equity award exercises on April 1, 2026. He exercised restricted stock units and stock options to acquire a total of 706,409 shares of common stock, including shares held indirectly through his spouse, with no open-market sales.
Following these transactions, Ram directly holds 4,649,088 shares of IGC Pharma common stock, while his spouse holds an additional 910,751 shares reported as indirect ownership. The filing reflects routine compensation-related vesting and option exercises rather than discretionary buying or selling.
IGC Pharma director James P. Moran reported routine equity compensation activity involving restricted stock units (RSUs). On April 1, 2026, he exercised 80,000 RSUs and 50,000 RSUs, each RSU converting into one share of IGC common stock at a $0.00 exercise price. These RSUs stem from grants made on June 20, 2023 and March 13, 2024 that vest in equal annual installments over three years. Following the conversions, Moran directly owns 1,235,735 shares of IGC Pharma common stock, with no open‑market sales disclosed in this filing.
IGC Pharma director and PFO Claudia Grimaldi exercised equity awards to acquire additional common stock. On April 1, 2026, she converted 100,000 Restricted Stock Units into 100,000 shares of common stock and exercised options for 138,462 shares at an exercise price of $0.26 per share.
These exercises increased her direct holdings to 1,372,714 shares of common stock. The RSUs and options were originally granted in June 2023 and March 2024, respectively, and vest in equal installments over three years.
IGC Pharma's CEO and director Ram Mukunda reported indirect transactions involving his spouse's holdings. On February 3, 2026, his spouse acquired 50,000 shares of common stock at $0.0 per share, bringing indirectly held common stock to 860,752 shares.
On the same date, the spouse was granted 16,667 restricted stock units that vest immediately and 66,666 restricted stock units that vest over time, both indirectly attributed "BY SPOUSE." Each restricted stock unit represents the right to receive one share of IGC common stock.
IGC Pharma director reports RSU conversion into common stock. On January 19, 2026, director Richard K. Prins exercised 100,000 restricted stock units, which were granted on March 13, 2024 and vest when specific board-approved milestones are achieved. Each unit represents the right to receive one share of IGC common stock, and the transaction was reported at an exercise price of $0.0 per unit. Following this transaction, Prins directly holds 1,371,251 shares of common stock and 50,000 restricted stock units.